HC Wainwright Estimates Genmab A/S FY2027 Earnings

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Investment analysts at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for Genmab A/S in a research report issued to clients and investors on Monday, September 14th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of $1.48 for the year. HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.17 per share.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.17. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.12 billion. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%.

A number of other analysts have also recently issued reports on the company. Guggenheim boosted their target price on Genmab A/S from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Weiss Ratings raised shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, September 1st. TD Cowen raised shares of Genmab A/S from a “hold” rating to a “buy” rating and lifted their price target for the company from $32.00 to $43.00 in a research report on Wednesday, July 22nd. New Street Research set a $43.00 price objective on shares of Genmab A/S in a research report on Wednesday, July 22nd. Finally, Truist Financial started coverage on shares of Genmab A/S in a research note on Wednesday, May 27th. They issued a “buy” rating and a $40.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $39.50.

Genmab A/S Stock Performance

Genmab A/S stock opened at $32.65 on Tuesday. The company has a market cap of $20.37 billion, a price-to-earnings ratio of 25.71, a price-to-earnings-growth ratio of 1.83 and a beta of 0.84. Genmab A/S has a 12 month low of $23.62 and a 12 month high of $35.43. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.46 and a quick ratio of 2.44. The stock’s 50-day moving average is $31.09 and its 200-day moving average is $28.28.

Hedge Funds Weigh In On Genmab A/S

A number of institutional investors have recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership boosted its position in Genmab A/S by 36.6% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock valued at $153,324,000 after buying an additional 1,334,919 shares during the last quarter. SBI Okasan Asset Management Co.Ltd. purchased a new stake in shares of Genmab A/S during the fourth quarter worth about $673,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Genmab A/S in the first quarter worth about $1,198,000. Diversify Wealth Management LLC purchased a new position in Genmab A/S in the first quarter valued at about $1,216,000. Finally, First Trust Advisors LP grew its stake in Genmab A/S by 84.3% during the 1st quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock valued at $66,038,000 after purchasing an additional 1,126,069 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering, developing and commercializing differentiated antibody-based medicines. The company’s research platforms include technologies designed to create human antibodies and bispecific antibodies that engage the immune system to target cancer and other serious diseases.

Genmab’s products and partnered medicines include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; Kesimpta (ofatumumab) for multiple sclerosis, developed with Novartis; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Pfizer.